Expertise in
1
conditions

Matthieu Schnee

CHD Vendee La Roche Sur Yon
La Roche, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
CHD Vendee La Roche Sur Yon
La Roche, FR 

Overview

Matthieu Schnee practices practicing medicine in La Roche, France.

Mr. Schnee is highly rated in 1 condition, according to our data. His clinical expertise encompasses Spontaneous Bacterial Peritonitis, Hepatitis, Hepatitis C, and Cirrhosis.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

CHD Vendee La Roche sur Yon
La Roche, France
Other Locations
Angers, 49100, France
Tours, France
97100, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Enrollment Status: Recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drugs: Oxaliplatin intravenous, 5 Fu, Folinic Acid, Oxaliplatin intra-arterial, Panitumumab, Bevacizumab
Study Phase: Phase 3
Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.
Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.
Enrollment Status: Completed
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Oxaliplatine, Folinic acid, Irinotecan, 5-FU
Study Phase: Phase 2
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: FOLFIRINOX, LV5FU2, FOLFIRI.3, Gemcitabine
Study Phase: Phase 2
Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .
Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Phase: Phase 2
Contribution of Percutaneous Endoscopic Caecostomie in the Management of Severe Constipation Refractory to Medical Treatment
Contribution of Percutaneous Endoscopic Caecostomie in the Management of Severe Constipation Refractory to Medical Treatment
Enrollment Status: Completed
Publish Date: January 27, 2023
Intervention Type: Device, Drug
Study Phase: Not Applicable
Coffee Consumption and NASH in the French Population.
Coffee Consumption and NASH in the French Population.
Enrollment Status: Completed
Publish Date: January 28, 2021
View 5 Less Clinical Trials

10 Total Publications

Association between obstructive sleep apnea and liver fibrosis in patients with suspected nonalcoholic fatty liver disease.
Association between obstructive sleep apnea and liver fibrosis in patients with suspected nonalcoholic fatty liver disease.
Journal: Sleep
Published: April 29, 2025

Frequently Asked Questions about Matthieu Schnee

Is Matthieu Schnee a top-rated expert for Spontaneous Bacterial Peritonitis?

MediFind is an objective health platform that identifies experts based on real-world data. Matthieu Schnee is classified as an Advanced expert for Spontaneous Bacterial Peritonitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Matthieu Schnee participate in research or clinical trials?

Yes. Matthieu Schnee has published 10 articles and abstracts on conditions like Spontaneous Bacterial Peritonitis. You can view a list of Matthieu Schnee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schnee's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile